In a 39-year-old woman with vulvar itching whose biopsy shows hyperkeratosis and parakeratosis without inflammation or dysplasia, what does this result indicate and how should it be managed?

Vulvar Biopsy Showing Hyperkeratosis and Parakeratosis: Interpretation and Management

This biopsy result showing hyperkeratosis and parakeratosis without inflammation or dysplasia is most consistent with lichen sclerosus (LS), and you should initiate treatment with clobetasol propionate 0.05% ointment using a 3-month tapering regimen while ensuring close follow-up to monitor for disease progression.

What This Result Means

The histologic findings of hyperkeratosis and parakeratosis in the context of vulvar itching strongly suggest lichen sclerosus, even when the classic inflammatory infiltrate is absent. The absence of inflammation does not exclude LS—particularly in early or treated disease. Critically, the absence of dysplasia is reassuring but does not eliminate the need for vigilant monitoring, as LS carries a 5-7% malignancy risk when untreated 1.

Key Diagnostic Considerations:

• Hyperkeratosis with parakeratosis is a hallmark feature of LS and represents the epidermal response to chronic inflammation
• The lack of inflammation may indicate early disease, partially treated disease, or the "burnt-out" phase of LS
• No dysplasia rules out vulvar intraepithelial neoplasia (VIN) at this time, but this can develop later if LS is inadequately controlled
• The clinical context of vulvar itching in a 39-year-old woman strongly supports LS as the diagnosis

Important caveat: While these findings are most consistent with LS, the British Association of Dermatologists guidelines emphasize that hyperkeratotic areas resistant to treatment require biopsy to exclude intraepithelial neoplasia or malignancy 2.

Immediate Management Algorithm

Step 1: Initiate First-Line Therapy

Start clobetasol propionate 0.05% ointment using the following 3-month regimen 2:

• Month 1: Once daily application
• Month 2: Alternate day application
• Month 3: Twice weekly application

Combine with:

• Soap substitute (emollient cleanser)
• Barrier preparation (emollient moisturizer)
• Strict avoidance of all irritant and fragranced products 2

Step 2: Patient Education (Critical)

Discuss the following with your patient 2:

• Amount to use: Fingertip unit measurements for vulvar application
• Site of application: Exact anatomical areas to treat
• Safety of ultrapotent steroids: Address concerns about package insert warnings regarding anogenital use, as these often lead to non-compliance 2
• Long-term nature of the condition requiring maintenance therapy

Step 3: Structured Follow-Up Schedule

First follow-up at 3 months 2:

• Assess treatment response
• Verify proper application technique
• Check for architectural changes (clitoral hood adhesions, labial fusion, introital stenosis)
• Document findings with diagram or photograph

Second follow-up at 6 months 2:

• Ensure disease control
• Address residual symptoms
• Establish maintenance regimen if needed

Management of Treatment Response

If Good Response:

• Continue individualized maintenance therapy with topical steroid to prevent scarring 2
• Titrate treatment to maintain symptom control and resolution of skin thickening and ecchymosis
• Annual follow-up with primary care physician 2
• Emphasize self-monitoring for new symptoms or changes

If Poor Response or Hyperkeratotic Areas Persist:

Refer to specialist vulval clinic 2 and consider:

• Intralesional triamcinolone (10-20 mg) for steroid-resistant hyperkeratotic areas, but only after repeat biopsy to exclude intraepithelial neoplasia or malignancy 2
• Systemic retinoids for hyperkeratotic LS 2
• Re-evaluation of diagnosis—consider differential diagnoses including lichen planus, psoriasis, or contact dermatitis 2

Critical Pitfalls to Avoid

1. Do not dismiss hyperkeratosis as benign: The British guidelines specifically state that hyperkeratotic LS often requires additional treatment and specialist referral 2. Your patient already has hyperkeratosis on biopsy.

2. Do not assume the diagnosis is final: If symptoms persist despite appropriate treatment, repeat biopsy is mandatory to exclude VIN or early malignancy 2

3. Do not neglect sexual function assessment: LS significantly impacts quality of life and sexual function 2. Address dyspareunia and psychosexual concerns proactively.

4. Do not undertreat: The absence of inflammation does not mean mild disease. Inadequate treatment increases malignancy risk and architectural complications.

5. Watch for vulvodynia: If LS appears controlled but burning/soreness persists (rather than itch), consider vulvodynia as a separate or coexisting condition 2

Long-Term Monitoring Rationale

The 5-7% malignancy risk with untreated LS is substantially reduced with adequate disease control 1. However, maintenance therapy is essential even in asymptomatic patients to prevent anatomic changes and reduce malignancy risk 1. The hyperkeratosis already present in your patient's biopsy places her in a higher-risk category requiring closer surveillance 2.